Carnitine Levels and Carnitine Supplementation in Type I Diabetes

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether type I diabetics with carnitine deficiency exhibit increased numbers of hypoglycemic (low blood sugars) events and if unrecognized hypoglycemia occurs during continuous 72-hour glucose monitoring. If they are determined to have unrecognized hypoglycemia, then oral carnitine supplementation will be given to those subjects and they will be reassessed for the number of hypoglycemic events in a 72-hour glucose monitoring.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Mercy Hospital Kansas City
• Collaborators: Leadiant Biosciences, Inc.; Minimed Pharmaceuticals; Pharmacia/Upjohn Career Development Award; Sigma Tau Pharmaceuticals, Inc.

Criteria

Inclusion Criteria:

• Diabetes Mellitus, Type I for greater than 2 years between the ages of 7 and 21

• currently on insulin replacement therapy

Exclusion Criteria:

• Patients with newly diagnosed Type I diabetes

• Patients already taking L-carnitine

• Patients who come to clinic without glucose monitors

• Patients with known seizure disorders not including hypoglycemic seizures

• Patients on metformin

• Patients with compromised renal function.